{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"22.8","value":"14.5"},{"comment":"Only 1 event occurred and 5 patients were censored. Therefor a median time to progression was not reached","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"* 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.\n* Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).\n* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.\n\nBKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.\n\nCisplatin: Cisplatin is a chemotherapy drug\n\nIntensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells","id":"OG000","title":"Dose Level 1"},{"description":"* 40 mg BKM120 will be administered orally daily for 45 days.\n* Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).\n* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.\n\nBKM120: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.\n\nCisplatin: Cisplatin is a chemotherapy drug\n\nIntensity-modulated radiotherapy (IMRT): IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells","id":"OG001","title":"Dose Level 2"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)","title":"Median Time to Progression","type":"SECONDARY","unitOfMeasure":"months"}